Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cytek Biosciences's Sloan Ratio for the quarter that ended in Mar. 2026 was -8.97%.
As of Mar. 2026, Cytek Biosciences has a Sloan Ratio of -8.97%, indicating the company is in the safe zone and there is no funny business with accruals.
Cytek Biosciences (NAS:CTKB) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Cytek Biosciences has a Sloan Ratio of -8.97%, indicating the company is in the safe zone and there is no funny business with accruals.
Cytek Biosciences Sloan Ratio % Related Terms
Cytek Biosciences Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs CERS, NPCE, CLPT: Sloan Ratio % Comparison
For the Medical Devices subindustry, Cytek Biosciences's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cytek Biosciences's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Cytek Biosciences's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -5.583 (Jun. 2025 ) + -5.478 (Sep. 2025 ) + -44.076 (Dec. 2025 ) + -18.866 (Mar. 2026 ) = $-74.0 Mil.
Cytek Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 0.108 (Jun. 2025 ) + -3.898 (Sep. 2025 ) + -0.771 (Dec. 2025 ) + -2.736 (Mar. 2026 ) = $-7.3 Mil.
Cytek Biosciences's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -16.413 (Jun. 2025 ) + 18.92 (Sep. 2025 ) + -1.842 (Dec. 2025 ) + -27.079 (Mar. 2026 ) = $-26.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (CTKB) has a Sloan Ratio % of -8.97% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cytek Biosciences and its competitors.
Is Cytek Biosciences' Sloan Ratio % too high?
Cytek Biosciences' current Sloan Ratio % is -8.97%. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Sloan Ratio % compare to CERS and NPCE?
Cytek Biosciences' Sloan Ratio % of -8.97% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cytek Biosciences and its competitors. Cytek Biosciences's current Sloan Ratio % is -8.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.83, compared to a current price of $4.63 — trading 20.6% below its estimated fair value. The current Sloan Ratio % is -8.97%. Cytek Biosciences' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Sloan Ratio % is -8.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.63 is trading 20.6% below its estimated GF Value™ of $5.83.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Sloan Ratio %: -8.97%
GF Value™: $5.83 vs. price of $4.63 (20.6% below fair value)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
